For brands replacing affected 7‑OH and kratom‑derivative product lines
MITRA-X™ is kratom extract produced through solvent‑free extraction, with mitragynine incorporated into a proprietary structured polyol matrix designed for oral delivery.
Carrier technology designed for improved bioavailability.
U.S. regulatory context
Reformulation landscape
Botanical kratom
Remains outside federal Controlled Substances Act scheduling.
Selected derivatives
MGPI, MGM‑15 and MGM‑16 are temporarily Schedule I.
Concentrated 7‑OH
DEA’s revised threshold-based scheduling proposal remains pending.
An ingredient platform for brands developing their next formulation.
For brands reassessing their kratom and derivative-based product lines.
U.S. position as of 29 October 2026. Product availability and permitted uses vary by jurisdiction.
The ingredient
Extraction and carrier, in one ingredient
Solvent-free kratom extraction
Made with kratom extract produced using a solvent-free extraction method.
Structured carrier technology
Mitragynine is incorporated into a proprietary structured polyol matrix designed for oral delivery.
Bioavailability
Designed to improve bioavailability
Up to
53%
Increase in bioavailability reported for the carrier platform
Designed for oral delivery
The structured carrier is designed to support dispersion and ingredient availability for oral absorption.
Carrier-platform result. Performance may vary by active ingredient and formulation.
Formulation
Four formulation advantages
Carrier design supports the properties that matter in product development.
Taste
Manage immediate bitterness through the carrier
Greater flexibility for flavour development
Water dispersion
Support rapid hydration and dispersion in water
Easier incorporation into aqueous formulations
Ingredient consistency
Distribute active material throughout the matrix
Control of ingredient loading
Format flexibility
Provide an engineered powder for oral systems
One ingredient platform across development programs
Taste and dispersion
Less bitterness, faster dissolution
>61%
Reduction in bitterness
Reported taste profiling of the carrier technology
83%
Faster dissolution
Reported versus raw crystals and powder blends
Carrier-platform results. Performance may vary by active ingredient and formulation.
Applications
Potential product formats
One ingredient platform for multiple formulation programs.
Tablets and oral melts
Solid oral formulations
Capsules
Powder fill systems
Powder formats
Stick packs and blended powders
Other oral formats
Drinks, concentrates and gummies
Applications are subject to formulation validation and applicable market requirements.
Development
How development works
A program moves through four stages, from the first brief to commercial supply.
- 01
Product brief
Define the product format, target market and ingredient requirements.
- 02
Sample evaluation
Assess taste, dispersion and processing behaviour in your formulation.
- 03
Product validation
Establish performance, ingredient uniformity and stability of the product.
- 04
Commercial supply
Discuss specifications, volumes and supply terms for your application.